查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1877439

抗感染药物市场：依药物类别、适应症、给药途径、最终用户、国家及地区划分－全球产业分析、市场规模、市场份额及2025-2032年预测

Anti-Infective Drugs Market, By Drug Class, By Indication, By Route of Administration, By End-User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 378 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年抗感染药物市场规模价值为 1,342.6721 亿美元，从 2025 年到 2032 年以 3.1% 的复合年增长率成长。

抗感染药物市场专注于研发和分销用于预防和治疗细菌、病毒、真菌和寄生虫感染的药物。医院感染率的上升和抗生素抗药性的日益严重，促使辉瑞和葛兰素史克等製药公司扩大其新型抗菌药物的研发管线。例如，世界卫生组织报告称，2023年有超过495万人死于抗药性感染，这使得对先进疗法的需求变得迫切。生技公司与学术界的合作正在推动下一代抗生素和抗病毒药物的研发。然而，抗生素的高昂研发成本和不断下降的利润阻碍了小型企业进入市场。新兴经济体治疗途径的扩大以及对联合疗法的日益重视，为企业提供了产品组合多元化和改善患者疗效的机会。

抗感染药物市场－市场动态

感染负担加重和抗菌素抗药性加剧推动抗感染药物创新

感染率上升和抗菌素抗药性日益严重，正促使全球卫生机构和製药公司加速抗感染药物的创新。根据世界卫生组织统计，抗菌素抗药性每年直接导致127万人死亡，另有368万人死于抗药性感染。这促使美国疾病管制与预防中心（CDC）等机构资助快速诊断工具和新型抗生素的研发计画。各国政府也支持公私合作项目，例如抗菌素抗药性行动基金，以因应抗生素研发管线日益萎缩的问题。这些努力正在推动新型抗菌药物、标靶抗病毒药物和联合疗法的研发，以更有效地对抗抗药性病原体。

抗感染药物市场細項分析：

全球抗感染药物市场按药物类别、适应症、给药途径、最终用户和地区进行细分。

根据药物类别，市场可分为四大类：抗菌药、抗霉菌药、抗寄生虫药和抗病毒药。抗菌药物占据最大市场份额，这主要得益于细菌感染治疗的广泛应用；其次是抗病毒药，这主要受病毒爆发日益增多的推动；抗真菌药物紧随其后，这主要与侵袭性真菌感染发病率的上升有关；而抗寄生虫药虽然市场份额较小，但在全球范围内却占据着至关重要的地位。

根据适应症，市场分为九大类：肺炎、败血症、结核病、皮癣菌病、念珠菌病、肝炎病毒感染、HIV感染、新冠病毒感染和抗甲氧西林金黄色葡萄球菌感染。肺炎因其全球负担沉重而位居榜首，其次是败血症，因为重症监护需求不断增加。 HIV感染和肝炎感染占据较大份额，且治疗项目仍在进行中，而结核病和耐甲氧西林金黄色葡萄球菌感染则推动了抗生素的研发。念珠菌病、皮癣菌病和新冠病毒感染是重点治疗领域。

抗感染药物市场—地域洞察

北美凭藉强大的医疗基础设施以及辉瑞和默克等企业持续的研发投入，在抗感染药物市场占据领先地位。 2018年，辉瑞与BioNTech合作，将基于mRNA的抗感染药物的应用范围拓展至新冠肺炎以外的领域，从而巩固了其在北美的市场地位。欧洲紧随其后，这得益于欧盟资助的抗菌素抗药性（AMR）计画以及葛兰素史克与生物医学高级研究与发展局（BARDA）合作开发新型抗生素等合作计画。亚太地区正崛起为重要的成长中心，这主要得益于不断上升的感染率以及各国政府为改善治疗可及性所做的努力；例如，印度的国家抗菌素抗药性行动计划提倡合理使用抗生素和本地化生产。拉丁美洲和中东及非洲地区的疫苗接种率不断提高，公共健康宣传活动也日益活跃。

抗感染药物市场—国家洞察

美国凭藉先进的医疗保健体系和强大的临床试验计画储备，在北美抗感染药物市场占据主导地位。 2024年，默克公司收购了Prometheus Biosciences公司，以增强其免疫学和传染病产品组合，并提升其研发能力。美国政府的生物医学高级研究与发展局（BARDA）持续资助与葛兰素史克（GSK）和Venatorx Pharmaceuticals等公司的合作，以加速抗生素的研发。美国疾病管制与预防中心（CDC）报告的多重抗药性感染病例不断增加，促使医院采用更新的疗法和诊断工具。美国食品药物管理局（FDA）强有力的监管框架以及《全球抗感染药物创新法案》（GAIN Act）等激励措施进一步促进了新型抗感染药物的创新和商业化。

抗感染药物市场－竞争格局：

抗感染药物市场的竞争格局由辉瑞、默克、葛兰素史克、强生和罗氏等产业领导者主导，这些企业正透过研发和策略交易不断拓展产品线。 2020年，辉瑞与吉利德科学公司合作，共同开发针对抗药性感染的新型抗病毒组合药物。葛兰素史克与美国生物医学高级研究与发展局（BARDA）的合作支持下一代抗生素的研发，而强生则投资于噬菌体研究以对抗超级细菌。像Venatorx Pharmaceuticals和Iterum Therapeutics这样的小型生物技术公司正与大型製药公司合作，以扩大生产和分销规模。这种合作、收购和政府支援项目的组合正在加剧竞争，并加速药物创新。

目录

第一章：抗感染药物市场概览

  • 研究范围
  • 市场估算年份

第二章：执行概要

  • 市集
    • 抗感染药物市场概况（按药物类别划分）
    • 抗感染药物市场概况（依适应症划分）
    • 抗感染药物市场概况（依给药途径划分）
    • 抗感染药物市场按最终用户分類的概况
    • 各国抗感染药物市场概况
    • 抗感染药物市场概况（按地区划分）
  • 竞争洞察

第三章：抗感染药物市场主要趋势

  • 抗感染药物市场驱动因素
    • 市场驱动因素的影响分析
  • 抗感染药物市场限制因素
    • 市场限制因素的影响分析
  • 抗感染药物市场机会
  • 抗感染药物市场未来趋势

第四章：抗感染药物产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景分析
  • 规范架构分析

第五章：抗感染药物市场：地缘政治紧张局势升级的影响

  • 新冠疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：抗感染药物市场概况

  • 抗感染药物市占率分析，2024年
  • 主要製造商细分数据
    • 知名球员分析
    • 新兴参与者分析

第七章：抗感染药物市场－依药物类别划分

  • 概述
    • 按药物类别分類的细分市场份额分析
    • 抗菌
      • β-内酰胺类抗生素
      • 奎诺酮类
      • 大环内酯类
      • 四环素
      • 氨基糖苷类
      • 其他的
    • 抗真菌药物
      • 唑类
      • 棘白菌素
      • 多烯类
    • 抗寄生虫药
    • 抗病毒药物

第八章：抗感染药物市场－依适应症划分

  • 概述
    • 按指标分類的细分市场占有率分析
    • 肺炎
    • 败血症
    • 结核
    • 皮癣菌病
    • 念珠菌病
    • 肝炎病毒感染
    • 爱滋病毒感染
    • 严重特殊传染性肺炎病毒
    • 抗甲氧西林金黄色葡萄球菌
    • 其他的

第九章：抗感染药物市场－依给药途径划分

  • 概述
    • 按给药途径分類的细分市占率分析
    • 口服
    • 注射剂
    • 主题
    • 吸入

第十章：抗感染药物市场－以最终用户划分

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院
    • 诊所
    • 零售药局
    • 机构买家

第十一章：抗感染药物市场－依地域划分

  • 介绍
    • 按地域分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美抗感染药物主要生产商
    • 北美市场规模及预测（按国家/地区划分）
    • 北美市场规模及预测（按药物类别划分）
    • 北美市场规模及预测（依适应症划分）
    • 北美市场规模及预测（依给药途径划分）
    • 北美市场规模及预测（依最终用户划分）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲抗感染药物主要生产商
    • 欧洲市场规模及预测（按国家/地区划分）
    • 欧洲市场规模及预测（按药物类别划分）
    • 欧洲市场规模及预测（依适应症划分）
    • 欧洲市场规模及预测（依给药途径划分）
    • 欧洲市场规模及预测（依最终用户划分）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区
    • 概述
    • 亚太地区抗感染药物主要生产商
    • 亚太市场规模及预测（依国家/地区划分）
    • 亚太地区市场规模及预测（依药物类别划分）
    • 亚太地区市场规模及预测（依适应症划分）
    • 亚太地区市场规模及预测（依给药途径划分）
    • 亚太市场规模及预测（依最终用户划分）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲抗感染药物主要生产商
    • 拉丁美洲市场规模及预测（按国家/地区划分）
    • 拉丁美洲市场规模及预测（按药物类别划分）
    • 拉丁美洲市场规模及预测（依适应症划分）
    • 拉丁美洲市场规模及预测（依给药途径划分）
    • 拉丁美洲市场规模及预测（按最终用户划分）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲抗感染药物主要生产商
    • MEA市场规模及预测（依国家/地区划分）
    • MEA市场规模及预测（依药物类别划分）
    • MEA市场规模及预测（依适应症划分）
    • MEA市场规模及预测（依给药途径划分）
    • MEA市场规模及预测（依最终用户划分）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 中东和非洲其他地区

第十二章：主要供应商分析－抗感染药物产业

  • 竞争格局分析
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • AbbVie
    • AstraZeneca
    • Bayer
    • Cipla
    • Dr. Reddy's Laboratories
    • Gilead Sciences
    • GlaxoSmithKline (GSK)
    • Glenmark Pharmaceuticals
    • Johnson & Johnson
    • Lupin
    • Merck & Co.
    • Novartis
    • Pfizer
    • Roche
    • Sandoz (Novartis)
    • Sanofi
    • Sun Pharmaceutical Industries
    • Teva Pharmaceutical Industries
    • Viatris
    • ViiV Healthcare
    • Others

第十三章：360度AnalystView

第十四章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5742

The Anti-Infective Drugs Market size was valued at US$ 134,267.21 Million in 2024, expanding at a CAGR of 3.1% from 2025 to 2032.

The anti-infective drugs market focuses on the development and distribution of medications used to prevent and treat infections caused by bacteria, viruses, fungi, and parasites. The rising incidence of hospital-acquired infections and increasing antibiotic resistance have pushed pharmaceutical companies like Pfizer and GlaxoSmithKline to expand their R&D pipelines for novel antimicrobials. For example, the WHO reported that over 4.95 million deaths in 2023 were linked to drug-resistant bacterial infections, creating urgent demand for advanced therapies. Partnerships between biotech firms and academia are supporting the development of next-generation antibiotics and antivirals. However, high development costs and declining profitability of antibiotics discourage smaller players from entering the market. Expanding access to treatments in emerging economies and the rising focus on combination therapies present opportunities for companies to diversify product portfolios and improve patient outcomes.

Anti-Infective Drugs Market- Market Dynamics

Rising Infection Burden and Antimicrobial Resistance Fuel Innovation in Anti-Infective Drugs

Rising infection rates and growing antimicrobial resistance are pushing global health agencies and pharmaceutical companies to accelerate innovation in anti-infective drugs. According to the WHO, antimicrobial resistance was responsible for 1.27 million direct deaths a year, with an additional 3.68 million deaths associated with drug-resistant infections. This has led organizations like the U.S. Centers for Disease Control and Prevention (CDC) to fund initiatives for rapid diagnostic tools and novel antibiotics. Governments are also supporting public-private partnerships, such as the AMR Action Fund, to address the dwindling antibiotic pipeline. These efforts are encouraging the development of new classes of antimicrobials, targeted antivirals, and combination therapies to combat resistant pathogens more effectively.

Anti-Infective Drugs Market- Segmentation Analysis:

The Global Anti-Infective Drugs Market is segmented on the basis of Drug Class, Indication, Route of Administration, End-User, and Region.

The market is divided into four categories based on Drug Class: Antibacterial, Antifungals, Antiparasitic, and Antivirals. Antibacterials hold the highest share due to widespread bacterial infection treatments, followed by antivirals driven by rising viral outbreaks. Antifungals rank next with the growing incidence of invasive fungal infections, while antiparasitics represent a smaller but crucial niche segment globally.

The market is divided into nine categories based on Indication: Pneumonia, Sepsis, Tuberculosis, Dermatophytosis, Candidiasis, Hepatitis virus infection, HIV infection, Covid-19 Virus, and Methicillin-resistant Staphylococcus Aureus. Pneumonia leads due to its high global burden, followed by sepsis, as critical care demand rises. HIV and hepatitis infections hold strong shares with ongoing treatment programs, while tuberculosis and MRSA drive antibiotic development. Candidiasis, dermatophytosis, and COVID-19 represent targeted therapeutic segments.

Anti-Infective Drugs Market- Geographical Insights

North America leads the anti-infective drugs market due to strong healthcare infrastructure and continuous R&D investments by players like Pfizer and Merck. In 2018, Pfizer collaborated with BioNTech to expand mRNA-based anti-infective applications beyond COVID-19, strengthening its regional presence. Europe follows closely, supported by EU-funded antimicrobial resistance (AMR) programs and partnerships like GSK's collaboration with BARDA to develop new antibiotics. Asia-Pacific is emerging as a key growth hub, driven by rising infection rates and government efforts to improve access to treatments; for instance, India's National Action Plan on AMR promotes antibiotic stewardship and local production. Latin America and MEA witness growing vaccine adoption and public health campaigns.

Anti-Infective Drugs Market- Country Insights

The United States dominates the North American anti-infective drugs market, supported by advanced healthcare systems and a robust pipeline of clinical trials. In 2024, Merck acquired Prometheus Biosciences to strengthen its immunology and infectious disease portfolio, enhancing its research capabilities. The U.S. government's Biomedical Advanced Research and Development Authority (BARDA) continues funding collaborations with companies like GSK and Venatorx Pharmaceuticals to accelerate antibiotic development. Rising cases of multidrug-resistant infections reported by the CDC are prompting hospitals to adopt newer therapies and diagnostic tools. Strong regulatory frameworks from the FDA and incentives like the GAIN Act further encourage innovation and commercialization of novel anti-infectives.

Anti-Infective Drugs Market- Competitive Landscape:

The competitive landscape of the anti-infective drugs market is shaped by leading players such as Pfizer, Merck, GSK, Johnson & Johnson, and Roche, who are expanding portfolios through R&D and strategic deals. In 2020, Pfizer partnered with Gilead Sciences to co-develop new antiviral combinations targeting resistant infections. GSK's collaboration with BARDA supports the development of next-generation antibiotics, while Johnson & Johnson invests in bacteriophage research to combat superbugs. Smaller biotech firms like Venatorx Pharmaceuticals and Iterum Therapeutics are entering collaborations with big pharma to scale manufacturing and distribution. This mix of partnerships, acquisitions, and government-backed programs is intensifying competition and accelerating drug innovation.

Recent Developments:

In February 2025, the Merieux Foundation, SPIM, and WHO launched a new Guide to Prescribing Anti-infective Drugs in Madagascar, updating antibiotic chapters, diagnostics, and integrating WHO's 2023 AWaRe classification to support standardized prescribing and strengthen national AMR action plans.

In February 2025, the U.S. FDA approved EMBLAVEO(TM) (aztreonam + avibactam) for adult patients with complicated intra-abdominal infections when few or no treatment options exist, including infections by E. coli and Klebsiella.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTI-INFECTIVE DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie
  • AstraZeneca
  • Bayer
  • Cipla
  • Dr. Reddy's Laboratories
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • Glenmark Pharmaceuticals
  • Johnson & Johnson
  • Lupin
  • Merck & Co.
  • Novartis
  • Pfizer
  • Roche
  • Sandoz (Novartis)
  • Sanofi
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries
  • Viatris
  • ViiV Healthcare
  • Others

GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Antibacterial
  • B-Lactams
  • Quinolones
  • Macrolides
  • Tetracycline
  • Aminoglycoside
  • Others
  • Antifungals
  • Azoles
  • Echinocandins
  • Polyenes
  • Antiparasitics
  • Antivirals

GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Pneumonia
  • Sepsis
  • Tuberculosis
  • Dermatophytosis
  • Candidiasis
  • Hepatitis virus infection
  • HIV infection
  • Covid-19 Virus
  • Methicillin-resistant Staphylococcus Aureus
  • Others

GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectable
  • Topical
  • Inhalation

GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Clinics
  • Retail Pharmacies
  • Institutional Buyers

GLOBAL ANTI-INFECTIVE DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Anti-Infective Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Anti-Infective Drugs Market Snippet by Drug Class
    • 2.1.2. Anti-Infective Drugs Market Snippet by Indication
    • 2.1.3. Anti-Infective Drugs Market Snippet by Route of Administration
    • 2.1.4. Anti-Infective Drugs Market Snippet by End-User
    • 2.1.5. Anti-Infective Drugs Market Snippet by Country
    • 2.1.6. Anti-Infective Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Anti-Infective Drugs Key Market Trends

  • 3.1. Anti-Infective Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Anti-Infective Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Anti-Infective Drugs Market Opportunities
  • 3.4. Anti-Infective Drugs Market Future Trends

4. Anti-Infective Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Anti-Infective Drugs Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Anti-Infective Drugs Market Landscape

  • 6.1. Anti-Infective Drugs Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Anti-Infective Drugs Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
    • 7.1.2. Antibacterial
      • 7.1.2.1. B-Lactams
      • 7.1.2.2. Quinolones
      • 7.1.2.3. Macrolides
      • 7.1.2.4. Tetracycline
      • 7.1.2.5. Aminoglycoside
      • 7.1.2.6. Others
    • 7.1.3. Antifungals
      • 7.1.3.1. Azoles
      • 7.1.3.2. Echinocandins
      • 7.1.3.3. Polyenes
    • 7.1.4. Antiparasitics
    • 7.1.5. Antivirals

8. Anti-Infective Drugs Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
    • 8.1.2. Pneumonia
    • 8.1.3. Sepsis
    • 8.1.4. Tuberculosis
    • 8.1.5. Dermatophytosis
    • 8.1.6. Candidiasis
    • 8.1.7. Hepatitis virus infection
    • 8.1.8. HIV infection
    • 8.1.9. Covid-19 Virus
    • 8.1.10. Methicilin-resistant Staphylococcus Aureus
    • 8.1.11. Others

9. Anti-Infective Drugs Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Injectable
    • 9.1.4. Topical
    • 9.1.5. Inhalation

10. Anti-Infective Drugs Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2024 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Clinics
    • 10.1.4. Retail Pharmacies
    • 10.1.5. Institutional Buyers

11. Anti-Infective Drugs Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Anti-Infective Drugs Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Anti-Infective Drugs Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Anti-Infective Drugs Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Anti-Infective Drugs Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Anti-Infective Drugs Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Anti-Infective Drugs Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. AbbVie
    • 12.2.2. AstraZeneca
    • 12.2.3. Bayer
    • 12.2.4. Cipla
    • 12.2.5. Dr. Reddy's Laboratories
    • 12.2.6. Gilead Sciences
    • 12.2.7. GlaxoSmithKline (GSK)
    • 12.2.8. Glenmark Pharmaceuticals
    • 12.2.9. Johnson & Johnson
    • 12.2.10. Lupin
    • 12.2.11. Merck & Co.
    • 12.2.12. Novartis
    • 12.2.13. Pfizer
    • 12.2.14. Roche
    • 12.2.15. Sandoz (Novartis)
    • 12.2.16. Sanofi
    • 12.2.17. Sun Pharmaceutical Industries
    • 12.2.18. Teva Pharmaceutical Industries
    • 12.2.19. Viatris
    • 12.2.20. ViiV Healthcare
    • 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us